Biora Therapeutics - BIOR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 2,114.02%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.68
▲ +0.0139 (2.09%)

This chart shows the closing price for BIOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biora Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOR

Analyst Price Target is $15.00
▲ +2,114.02% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Biora Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 2,114.02% upside from the last price of $0.68.

This chart shows the closing price for BIOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Biora Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
1/2/2024HC WainwrightReiterated RatingBuy ➝ BuyLow
8/15/2023HC WainwrightReiterated RatingBuy ➝ BuyLow
7/14/2022HC WainwrightBoost Target$2,500.00 ➝ $3,750.00Low
2/24/2022Raymond JamesLower Target$55.00 ➝ $42.00High
11/4/2021StephensDowngradeOverweight ➝ Equal WeightHigh
10/14/2021HC WainwrightInitiated CoverageBuy$4.00High
7/29/2021Piper SandlerBoost TargetOverweight$3.00 ➝ $5.00High
6/3/2021Piper SandlerLower TargetOverweight$8.00 ➝ $3.00High
6/3/2021Robert W. BairdDowngradeOutperform ➝ Neutral$4.00 ➝ $2.00High
6/2/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
5/17/2021Wells Fargo & CompanyLower TargetUnderweight$4.00 ➝ $2.00High
5/14/2021Raymond JamesLower TargetOutperform$10.00 ➝ $7.00High
5/14/2021Robert W. BairdLower TargetOutperform$6.00 ➝ $4.00Medium
3/21/2021Robert W. BairdReiterated RatingBuy$6.00Low
2/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$5.00High
1/14/2021Piper SandlerLower TargetOverweight$15.00 ➝ $10.00High
11/10/2020Raymond JamesLower TargetOutperform$15.00 ➝ $10.00High
11/10/2020Piper SandlerLower TargetAverage ➝ Overweight$17.00 ➝ $15.00High
10/23/2020BTIG ResearchInitiated CoverageBuy$12.00Low
8/19/2020Raymond JamesReiterated RatingBuyHigh
7/14/2020Piper SandlerInitiated CoverageOverweight$17.00High
7/14/2020Robert W. BairdInitiated CoverageOutperform$12.00Medium
7/14/2020Raymond JamesInitiated CoverageOutperform$15.00High
7/14/2020Wells Fargo & CompanyInitiated CoverageOverweight$11.00High
(Data available from 7/15/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/17/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biora Therapeutics logo
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.68
Low: $0.66
High: $0.68

50 Day Range

MA: $0.68
Low: $0.50
High: $0.76

52 Week Range

Now: $0.68
Low: $0.48
High: $4.22

Volume

87,600 shs

Average Volume

361,992 shs

Market Capitalization

$24.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Biora Therapeutics?

The following equities research analysts have issued stock ratings on Biora Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for BIOR.

What is the current price target for Biora Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Biora Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 2,114.0%. HC Wainwright has the highest price target set, predicting BIOR will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Biora Therapeutics in the next year.
View the latest price targets for BIOR.

What is the current consensus analyst rating for Biora Therapeutics?

Biora Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIOR will outperform the market and that investors should add to their positions of Biora Therapeutics.
View the latest ratings for BIOR.

What other companies compete with Biora Therapeutics?

Other companies that are similar to Biora Therapeutics include Renalytix, Exagen, Cue Biopharma, Enzo Biochem and CervoMed. Learn More about companies similar to Biora Therapeutics.

How do I contact Biora Therapeutics' investor relations team?

Biora Therapeutics' physical mailing address is 4330 La Jolla Village Dr Ste 200, San Diego, California 92122. The company's listed phone number is 833-727-2841 and its investor relations email address is [email protected]. The official website for Biora Therapeutics is www.bioratherapeutics.com. Learn More about contacing Biora Therapeutics investor relations.